Screen Shot 2019-02-26 at 6.11.44 PM.png


Stroke is one of Australia’s biggest killers and a leading cause of disability. In 2017 there were more than 56,000 new and recurrent strokes – that is one stroke every nine minutes. The financial cost of stroke in Australia is estimated to be $5 billion each year.

The Stroke Foundation’s comprehensive Clinical Guidelines for Stroke Management are evolving into living guidelines as a next generation solution for health evidence translation in stroke..

This three-year pilot project will build and evaluate a world-first, online, dynamically updating summary of stroke evidence to guide clinical practice and policy development. The project is a partnership between the Stroke Foundation and Cochrane Australia, and is supported by the Australian government’s Medical Research Future Fund.

For more information please contact 



Diabetes is an National Health Priority area that affects approx. 1.7 million Australians and represents an estimated $15 billion per annum in direct and indirect costs to the Australian economy.

As part of the implementation plan for the Australian National Diabetes Strategy 2016-2020, several key diabetes organisations are partnering to establish two living evidence demonstration projects in areas that reflect a high priority for decision making in diabetes management, and where there is uncertainty in the existing evidence and a high likelihood of emerging evidence:

  1. Recommendations for which therapies are best for blood glucose control in type 2 diabetes?

  2. Recommendations for the use of technology for managing diabetes (eg pumps, continuous glucose monitoring, flash glucose monitoring).

The LG4D project is a partnership between Australian Diabetes Society, Diabetes Australia, Australian Diabetes Educators Association, Australasian Paediatric Endocrine Group and Cochrane Australia and is supported by the Australian government Department of Health.

For more information about this frontier project please contact Heath White,

Screen Shot 2019-02-26 at 6.16.53 PM.png
Screen Shot 2019-02-26 at 6.11.44 PM.png


Arthritis and musculoskeletal (MSK) conditions like back pain affect more than 6 million Australians and are the fourth leading contributor to Australia’s total burden of illness.

As part of a comprehensive program of MSK research funded under the NHMRC Centres of Research Excellence scheme, the Australian and New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC) is working to establish living systematic reviews of treatments for common MSK conditions.

This includes a living review and network meta-analysis of all available drugs for rheumatoid arthritis. The project aims to provide a living dataset that is open for use by guideline developers to support living evidence-based guideline recommendations.

For more information about this frontier project please contact Dr Sam Whittle,



Chronic kidney disease is a significant and growing public health issue, responsible for a substantial burden of illness and premature mortality. Every day, around 60 people in Australia die with kidney-related disease and 1 in 3 Australians are at risk of developing chronic kidney disease.

Kidney Health Australia has a long history of supporting the development and implementation of reliable and trustworthy clinical practice guidelines from early stage chronic kidney disease, through to dialysis, and kidney transplantation through the Kidney Health Australia - Caring for Australasians with Renal Impairment (KHA-CARI) Guidelines program.

A group of leading kidney health specialists, systematic reviewers and guideline developers in Australia are currently working to develop a world-first Living Evidence pilot project in kidney health.

For more information about this frontier project please contact the KHA-CARI Guidelines Office.

Screen Shot 2019-02-26 at 6.16.53 PM.png
Screen Shot 2019-02-26 at 6.11.44 PM.png


Heart disease is Australia’s leading single cause of death. Heart disease also has a significant impact on the economy – for example, ischaemic heart disease costs Australia around $7.3b per year. There were 18,590 Australian lives lost to heart disease in 2017.

The Heart Foundation is a major funder and developer of clinical practice guidelines and decision aids for the prevention, screening, diagnosis, and management of heart disease (including acute coronary syndromes, atrial fibrillation, heart failure, hypertension, and absolute cardiovascular risk).

The Heart Foundation joined the Australian Living Evidence Consortium in January 2019 to develop a pilot living guideline project and is currently undertaking scoping and prioritisation to identify suitable topic areas.

For more information please contact Cia Connell,


If you’d like to discuss developing a Living Evidence project or explore other opportunities for collaborating with us, please get in touch–we’d love to hear from you.

Back to top

Screen Shot 2019-02-26 at 6.16.53 PM.png